The Motley FoolWed, 18 Mar 2026 15:21:41 GMTWhat to Make of VR Adviser's Big Ocular Therapeutix Sell-DownOCUL+10.84%
Seeking AlphaMon, 02 Mar 2026 21:37:53 GMTOcular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD TranscriptOCUL+10.84%
Seeking AlphaTue, 17 Feb 2026 21:15:00 GMTOcular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD TranscriptOCUL+10.84%
Zacks Investment ResearchThu, 05 Feb 2026 14:11:07 GMTOcular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue EstimatesOCUL+10.84%
Seeking AlphaWed, 04 Feb 2026 12:30:03 GMTOcular Therapeutix: Why SOL-1 Trial Outcome Is Likely PositiveOCUL+10.84%